menu
    • menu

    Company profile for Tarveda Therapeutics

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Tarveda Therapeutics is discovering and developing a new class of potent and selective precision oncology medicines for the treatment of patients with various solid tumor malignancies. Our strategy includes developing our own proprietary Pentarin miniature conjugates to enhance the effectiveness of promising anti-cancer payloads that have struggled without their selective targeting to solid tumors.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Tarveda TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    134 Coolidge Avenue Watertown, MA 02472
    Telephone
    Telephone
    617.923.4100
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.tarvedatx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/blend-therapeutics
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tarveda Therapeutics Announces Data from Phase 2 Trial of PEN-221
    Tarveda Therapeutics Announces Data from Phase 2 Trial of PEN-221

    01 Nov 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211101005129/en/Tarveda-Therapeutics-Announces-Data-from-Phase-2-Trial-of-PEN-221-to-Be-Presented-at-NANETS-2021-Multidisciplinary-NET-Virtual-Symposium

    BUSINESSWIRE
    01 Nov 2021
    Share Share
    Tarveda and SciClone expand License Agreement for HSP90-PI3K Drug Conjugates
    Tarveda and SciClone expand License Agreement for HSP90-PI3K Drug Conjugates

    16 Sep 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210916005821/en

    BUSINESSWIRE
    16 Sep 2021
    Share Share
    Tarveda to Present Data from Phase 2 Study of PEN-221 at ASCO Meeting
    Tarveda to Present Data from Phase 2 Study of PEN-221 at ASCO Meeting

    20 May 2021

    // BIOSPACE

    https://www.biospace.com/article/releases/tarveda-therapeutics-to-present-data-from-phase-2-study-of-pen-221-at-2021-asco-annual-meeting/

    BIOSPACE
    20 May 2021
    Share Share
    Tarveda Therapeutics Publishes Preclinical Study Evaluating HSP90 Binding
    Tarveda Therapeutics Publishes Preclinical Study Evaluating HSP90 Binding

    04 Aug 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200804005646/en

    BUSINESSWIRE
    04 Aug 2020
    Share Share
    Tarveda Therapeutics Publishes Preclinical Study Evaluating HSP90
    Tarveda Therapeutics Publishes Preclinical Study Evaluating HSP90

    04 Aug 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200804005646/en/Tarveda-Therapeutics-Publishes-Preclinical-Study-Evaluating-HSP90

    BUSINESSWIRE
    04 Aug 2020
    Share Share
    Tarveda Therapeutics Reports Complete Data from of Ph 1/2a Study of PEN-866
    Tarveda Therapeutics Reports Complete Data from of Ph 1/2a Study of PEN-866

    13 May 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200513005744/en

    BUSINESSWIRE
    13 May 2020
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search